XML 173 R52.htm IDEA: XBRL DOCUMENT
v3.24.3

Stockholders’ Deficiency (Details) |  |  |  |  |  |  |  | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jan. 19, 2024 USD ($) $ / shares shares | Dec. 22, 2023 USD ($) $ / shares shares | Nov. 08, 2023 USD ($) $ / shares shares | Oct. 16, 2023 USD ($) $ / shares shares | Aug. 31, 2023 USD ($) $ / shares shares | Aug. 29, 2023 USD ($) shares | May 30, 2023 USD ($) $ / shares shares | Jan. 31, 2024 shares | Jun. 30, 2024 USD ($) $ / shares shares | Jun. 30, 2023 USD ($) shares | Jun. 30, 2024 USD ($) $ / shares shares | Jun. 30, 2023 USD ($) | Dec. 31, 2023 USD ($) $ / shares shares | Dec. 31, 2023 CAD ($) shares | Dec. 31, 2022 USD ($) $ / shares shares | Jun. 30, 2024 $ / shares | Dec. 31, 2023 $ / shares | Dec. 22, 2023 $ / shares shares | Dec. 04, 2023 $ / shares | Mar. 15, 2023 $ / shares shares | Feb. 16, 2023 $ / shares shares
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Convertible ratio |  |  |  |  |  |  |  |  |  |  | 1:1 |  |  | 1:1 |  | 1:1 |  |  |  |  |  |  |  |
Share issuance costs |  |  |  |  |  |  |  |  |  |  | 180,000 |  |  |  |  |  |  | 350,000 |  |  |  |  |  |
Exercise price | (per share) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0.255 |  | $ 0.31 |  |
Proceeds from issuance of private placements |  |  |  |  |  |  |  |  |  |  | $ 1,800 |  |  | $ 47,495 |  | $ 6,055,650 |  | $ 3,500 |  |  |  |  |  |
Number of warrant issued |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,277,007 |  |  |  |  |  |  |  |  |  |
Purchase of each warrant |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 |  |  |  |  |  |  |  |  |  |
Commission paid (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 172,480 |  |  |  |  |  |  |  |  |  |
Legal fees (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  | 15,428 |  |  |  |  |  |  |  |  |  |
Exercisable date |  | Dec. 22, 2026 | Nov. 08, 2026 | Oct. 16, 2026 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of value (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  | (405,753) |  | $ (208,686) | (1,055,985) |  |  |  |  |  |  |  |  |  |
Additional paid-in capital to share capital (in Dollars) | $ |  | $ 80,039 |  |  |  |  |  |  |  |  | $ 89,631 |  |  | 1,344,480 |  |  |  | $ 174,285 |  |  |  |  |  |
Option price per share (in Dollars per share) | $ / shares |  |  |  |  |  |  |  |  |  |  | $ 0.01 |  |  |  |  |  |  | $ 0.01 |  |  |  |  |  |
Proceeds from issuance of units (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 27,000 |  |  |  |  |  |  |  |  |  |
Aggregate proceeds percentage |  |  |  |  |  |  | 10.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant percentage |  |  |  |  |  |  | 10.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gross proceeds percentage |  |  |  |  |  |  | 5.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common shares, shares issued |  | 86,101 |  |  |  |  |  |  | 150,505,536 |  | 150,505,536 |  |  | 118,208,989 |  |  |  | 61,023,450 |  |  | 86,101 |  |  |
Warrants |  |  |  |  | 6,118,808 |  |  |  |  |  |  |  |  | 43,729,794 |  |  |  |  |  |  |  |  |  |
Terms of expected life years |  |  |  |  | 3 years 2 months 19 days |  |  |  |  |  |  |  |  | 4 years 1 month 24 days |  | 4 years 1 month 24 days |  |  |  |  |  |  |  |
Percentage of volatility rate |  |  |  |  | 110.00% |  |  |  |  |  |  |  |  | 87.00% |  | 87.00% |  |  |  |  |  |  |  |
Revaluation of derivative liability (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 4,025,102 |  |  |  |  |  |  |  |  |  |
Reclassification charges equity (in Dollars) | $ |  |  |  |  | $ 4,541,545 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Decrease of share capital (in Dollars) | $ |  |  |  |  | $ 4,541,545 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Repriced of warrants |  |  |  |  |  |  |  |  |  |  |  |  |  | 11,777,336 |  | 11,777,336 |  |  |  |  |  |  |  |
Reclassification of exercise price (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  | $ 3,942,575 |  |  |  |  |  |  |  |  |  |  |  |  |
Derivative liability loss on revaluation (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  | $ 432,933 |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of grant non-transferable share options |  |  |  |  |  |  |  |  |  |  | 20.00% |  |  |  |  |  |  |  |  |  |  |  |  |
Unrecognized share-based compensation expense (in Dollars) | $ |  |  |  |  |  |  |  |  | $ 581,391 |  | $ 581,391 |  |  | $ 1,188,800 |  |  |  |  |  |  |  |  |  |
Issuance of common shares |  |  |  |  |  |  |  |  | 165,000 |  | 165,000 |  |  | 165,000 |  |  |  |  |  |  |  |  |  |
Consulting fee (in Dollars) | $ |  |  | $ 160,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value of warrants (in Dollars) | $ |  |  |  |  |  |  |  |  | $ (187,056) | $ 71,856 | $ 432,933 |  | 16,658 | $ 4,085,284 |  |  |  | $ (1,823,444) |  |  |  |  |  |
Reallocated common shares (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,394,858 |  |  |  |  |  |  |  |  |  |
Gain (loss) on derivative liability (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  | 145,980 |  |  |  | $ 1,658,486 |  |  |  |  |  |
Incremental fair value (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 98,017 |  |  |  |  |  |  |  |  |  |
Warrant [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of warrant issued |  |  |  |  |  |  |  |  |  |  |  |  |  | 11,317,750 |  |  |  |  |  |  |  |  | 459,586 |
Purchase of each warrant |  |  |  |  |  |  | 1 |  |  |  |  |  |  | 3,322,471 |  |  |  |  |  |  |  |  |  | 6,097,579
Warrant exercise price per share | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0.39 |  |  |  |
Estimated fair value for adjustment (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  | $ 582,245 |  |  | $ 73,018 |  |  |  |  |  |  |  |  |  |
Warrant term |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 years |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  | 6,118,808 |  |  |  | 61,332,886 |  | 61,332,886 |  |  | 11,970,312 |  |  |  |  |  |  |  |  |  |
Terms of expected life years |  |  |  |  | 1 year |  |  |  |  |  | 3 years |  |  | 5 years |  | 5 years |  | 1 year 7 months 24 days |  |  |  |  |  |
Percentage of volatility rate |  |  |  |  | 131.00% |  |  |  |  |  | 101.01% |  |  | 108.71% |  | 108.71% |  | 93.00% |  |  |  |  |  |
Percentage of discount rate |  |  |  |  |  |  |  |  |  |  | 3.77% |  |  | 3.05% |  | 3.05% |  |  |  |  |  |  |  |
Amount of dividend yield (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0 |  |  |  |  |  |  |  |  |  |
Revaluation of derivative liability (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  | 145,980 |  |  |  |  |  |  |  |  |  |
Reclassification charges equity (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  | $ 351,969 |  |  | 351,969 |  |  |  |  |  |  |  |  |  |
Repriced of warrants |  |  |  |  |  |  |  |  |  |  | 9,420,050 |  |  |  |  |  |  |  |  |  |  |  |  |
Reclassification of exercise price (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,541,545 |  |  |  |  |  |  |  |  |  |
Percentage of grant non-transferable share options |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value of warrants (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,394,858 |  |  |  |  |  |  |  |  |  |
Agents warrants [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of warrant issued |  |  |  |  |  |  |  |  |  |  |  |  |  | 324,642 |  |  |  |  |  |  |  |  |  |
Warrant exercise price per share | $ / shares |  |  |  |  |  |  |  |  | $ 0.31 |  | $ 0.31 |  |  | $ 0.39 |  |  |  |  |  |  |  |  |  |
Estimated fair value for adjustment (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 618,004 |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  | 1,037,330 |  | 1,037,330 |  |  | 324,642 |  |  |  |  |  |  |  |  |  |
Warrant Liability [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revaluation of derivative liability (in Dollars) | $ |  |  |  |  |  |  |  |  | $ 351,969 |  | $ 351,969 |  |  | $ 351,969 |  |  |  |  |  |  |  |  |  |
Common Stock [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share issuance costs |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,129,566 |  | 2,129,566 |  |  |  |  |  |  |  |
Warrant exercise price per share | $ / shares |  |  |  |  |  |  |  |  | $ 0.4 |  | $ 0.4 |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of value (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  | $ (987,998) |  | $ (281,704) | $ (1,458,151) |  |  |  |  |  |  |  |  |  |
Shares exercised |  |  |  |  |  |  |  | 192,500 | 180,000 | 1,050,000 | 372,500 |  |  | 2,865,000 |  | 2,865,000 |  | 416,519 |  |  |  |  |  |
Additional paid-in capital to share capital (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,344,480 |  |  |  |  |  |  |  |  |  |
Escrow Shares |  |  |  |  |  |  |  |  |  |  |  |  |  | 11,502,874 |  |  |  |  |  |  |  |  |  |
ACI Canada Legacy Performance Options [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares exercised |  |  |  |  |  |  |  |  |  |  | 180,000 |  |  | 2,700,000 |  | 2,700,000 |  | 350,000 |  |  |  |  |  |
Restricted Stock Units (RSUs) [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Restricted shares |  |  |  |  |  | 7,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from converted of common shares (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Black-Scholes Option Pricing Model [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gain (loss) on derivative liability (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 3,939,304 |  |  |  |  |  |  |  |  |  |
Black-Scholes Option Pricing Model [Member] | Warrant [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated fair value for adjustment (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  | $ 946,105 |  |  | 4,455,747 |  |  |  |  |  |  |  |  |  |
Gain (loss) on derivative liability (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,455,747 |  |  |  |  |  |  |  |  |  |
Equity Option [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Additional paid-in capital to share capital (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 80,039 |  |  |  |  |  |  |  |  |  |
Common shares, shares issued |  |  |  |  |  |  |  |  |  |  |  |  |  | 86,101 |  |  |  |  |  |  |  |  |  |
Percentage of grant non-transferable share options |  |  |  |  |  |  |  |  |  |  |  |  |  | 20.00% |  | 20.00% |  |  |  |  |  |  |  |
Restricted Stock [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Escrow Shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,116,518 |  |  |  |  |  |
"PP Tranche 5” [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share issuance costs | 16,965,762 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price | $ / shares | $ 0.22 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from issuance of private placements | $ | $ 3,732,469 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant exercise price per share | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0.31 |  |  |  |  |
Commission paid (in Dollars) | $ | 391,178 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Legal fees (in Dollars) | $ | $ 14,575 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  | 16,965,762 |  | 16,965,762 |  |  |  |  |  |  |  |  |  |  |  |  |
"PP Tranche 5” [Member] | Warrant [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant exercise price per share | $ / shares | $ 0.31 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercisable date | Jan. 19, 2027 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
"PP Tranche 5” [Member] | Agents warrants [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of warrant issued | 1,037,330 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase of each warrant | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated fair value for adjustment (in Dollars) | $ | $ 582,245 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
"PP Tranche 5” [Member] | Common Stock [Member] | Warrant [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of warrant issued | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase of each warrant | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Over-Allotment Option [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aggregate proceeds percentage |  |  |  |  |  |  | 30.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
PP Tranche 2 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share issuance costs |  |  |  | 1,596,830 |  |  |  |  |  |  |  |  |  | 23,747,648 |  | 23,747,648 |  |  |  |  |  |  |  |
Exercise price | (per share) |  |  |  | $ 0.22 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0.255 |  |  |  |
Proceeds from issuance of private placements |  |  |  | $ 351,303 |  |  |  |  |  |  |  |  |  | $ 4,506,055 |  | $ 6,055,650 |  |  |  |  |  |  |  |
Number of warrant issued |  |  |  | 78,181 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase of each warrant |  |  |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant exercise price per share | $ / shares |  |  |  | $ 0.31 |  |  |  |  |  |  |  |  |  | $ 0.31 |  |  |  |  |  |  |  |  |  |
Commission paid (in Dollars) | $ |  |  |  | $ 51,600 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Legal fees (in Dollars) | $ |  |  |  | 5,371 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated fair value for adjustment (in Dollars) | $ |  |  |  | $ 10,199 |  |  |  |  |  |  |  |  |  | $ 10,199 |  |  |  |  |  |  |  |  |  |
Exercisable date |  |  |  | Oct. 16, 2026 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  | 798,414 |  |  |  |  |  |  |  |  |  |
Terms of expected life years |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 years |  | 3 years |  |  |  |  |  |  |  |
Percentage of volatility rate |  |  |  |  |  |  |  |  |  |  |  |  |  | 90.98% |  | 90.98% |  |  |  |  |  |  |  |
Percentage of discount rate |  |  |  |  |  |  |  |  |  |  |  |  |  | 4.60% |  | 4.60% |  |  |  |  |  |  |  |
Amount of dividend yield (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
PP Tranche 2 [Member] | Warrant [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase of each warrant |  |  |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant exercise price per share | $ / shares |  |  |  | $ 0.31 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
PP Tranche 2 [Member] | Agents warrants [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of warrant issued |  |  |  | 78,181 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant exercise price per share | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0.31 |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  | 78,181 |  |  |  |  |  |  |  |  |  |
Private Placement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share issuance costs |  |  |  |  |  |  |  |  |  |  |  |  |  | 23,747,648 |  | 23,747,648 |  |  |  |  |  |  |  |
Exercise price | $ / shares |  |  |  |  |  |  | $ 0.22 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from issuance of private placements | $ |  |  |  |  |  |  | $ 6,500,000 |  |  |  |  |  |  | $ 4,506,055 |  |  |  |  |  |  |  |  |  |
Warrant exercise price per share | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0.39 |  |  |  |
Warrant term |  |  |  |  |  |  |  |  |  |  |  |  |  | 5 years |  |  |  |  |  |  |  |  |  |
PP Tranche 1 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share issuance costs |  |  |  |  | 272,803 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase of each warrant |  |  |  |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant exercise price per share | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0.31 |  |  |  |  |  |  |  |  |  |
Commission paid (in Dollars) | $ |  |  |  |  | $ 180,051 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Legal fees (in Dollars) | $ |  |  |  |  | 28,334 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated fair value for adjustment (in Dollars) | $ |  |  |  |  | $ 44,292 |  |  |  |  |  |  |  |  | $ 44,292 |  |  |  |  |  |  |  |  |  |
Exercisable date |  |  |  |  | Aug. 31, 2026 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,057,025 |  |  |  |  |  |  |  |  |  |
Terms of expected life years |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 years |  | 3 years |  |  |  |  |  |  |  |
Percentage of volatility rate |  |  |  |  |  |  |  |  |  |  |  |  |  | 91.24% |  | 91.24% |  |  |  |  |  |  |  |
Percentage of discount rate |  |  |  |  |  |  |  |  |  |  |  |  |  | 4.40% |  | 4.40% |  |  |  |  |  |  |  |
Amount of dividend yield (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0 |  |  |  |  |  |  |  |  |  |
PP Tranche 1 [Member] | Warrant [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant exercise price per share | $ / shares |  |  |  |  | $ 0.31 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
PP Tranche 1 [Member] | Agents warrants [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of warrant issued |  |  |  |  | 272,803 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase of each warrant |  |  |  |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant exercise price per share | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0.31 |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  | 272,803 |  |  |  |  |  |  |  |  |  |
PP Tranche 3 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share issuance costs |  |  | 4,590,903 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price | $ / shares |  |  | $ 0.22 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from issuance of private placements | $ |  |  | $ 1,009,999 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase of each warrant |  |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant exercise price per share | $ / shares |  |  | $ 0.31 |  |  |  |  |  |  |  |  |  |  | $ 0.31 |  |  |  |  |  |  |  |  |  |
Commission paid (in Dollars) | $ |  |  | $ 151,500 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Legal fees (in Dollars) | $ |  |  | 10,501 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated fair value for adjustment (in Dollars) | $ |  |  | $ 24,692 |  |  |  |  |  |  |  |  |  |  | $ 24,692 |  |  |  |  |  |  |  |  |  |
Exercisable date |  |  | Nov. 08, 2026 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,295,449 |  |  |  |  |  |  |  |  |  |
Terms of expected life years |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 years |  | 3 years |  |  |  |  |  |  |  |
Percentage of volatility rate |  |  |  |  |  |  |  |  |  |  |  |  |  | 91.31% |  | 91.31% |  |  |  |  |  |  |  |
Percentage of discount rate |  |  |  |  |  |  |  |  |  |  |  |  |  | 4.00% |  | 4.00% |  |  |  |  |  |  |  |
Amount of dividend yield (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
PP Tranche 3 [Member] | Warrant [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant exercise price per share | $ / shares |  |  | $ 0.31 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
PP Tranche 3 [Member] | Agents warrants [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of warrant issued |  |  | 229,544 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant exercise price per share | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0.31 |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  | 229,544 |  |  |  |  |  |  |  |  |  |
PP Tranche 4 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share issuance costs |  | 722,771 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of warrant issued |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 |  |  |
Purchase of each warrant |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 |  |  |
Warrant exercise price per share | $ / shares |  | $ 0.31 |  |  |  |  |  |  |  |  |  |  |  | $ 0.31 |  |  |  |  |  |  |  |  |  |
Commission paid (in Dollars) | $ |  | $ 238,515 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated fair value for adjustment (in Dollars) | $ |  | 249,965 |  |  |  |  |  |  |  |  |  |  |  | $ 249,965 |  |  |  |  |  |  |  |  |  |
Proceeds from issuance of units (in Dollars) | $ |  | $ 2,011,137 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Units per share (in Dollars per share) | $ / shares |  | $ 0.22 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  | 9,141,534 |  |  |  |  |  |  |  |  |  |
Terms of expected life years |  |  |  |  |  |  |  |  |  |  |  |  |  | 3 years |  | 3 years |  |  |  |  |  |  |  |
Percentage of volatility rate |  |  |  |  |  |  |  |  |  |  |  |  |  | 91.75% |  | 91.75% |  |  |  |  |  |  |  |
Percentage of discount rate |  |  |  |  |  |  |  |  |  |  |  |  |  | 3.70% |  | 3.70% |  |  |  |  |  |  |  |
Amount of dividend yield (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
PP Tranche 4 [Member] | Agents warrants [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant exercise price per share | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0.31 |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  | 722,771 |  |  |  |  |  |  |  |  |  |
First Tranche [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant exercise price per share | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0.39 |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  | 16,795,221 |  |  |  |  |  |  |  |  |  |
Second Tranche [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant exercise price per share | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0.39 |  |  |  |  |  |  |  |  |  |
Warrants |  |  |  |  |  |  |  |  |  |  |  |  |  | 6,952,427 |  |  |  |  |  |  |  |  |  |
Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant exercise price per share | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0.39 | $ 0.39
Minimum [Member] | Warrant [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant exercise price per share | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0.39 | 0.39
Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant exercise price per share | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0.289 | 0.283
Maximum [Member] | Warrant [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant exercise price per share | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0.289 | $ 0.283
Equity Option [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares exercised |  |  |  |  |  |  |  |  |  |  | 272,840 | [1] |  | 251,101 | [2] | 251,101 | [2] | 66,519 |  |  |  |  |  |
Equity Option [Member] | Warrant [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of warrant issued |  |  |  |  |  |  |  |  |  |  |  |  |  | 324,642 |  |  |  |  |  |  |  |  |  |
2022 Option Plan [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of grant non-transferable share options |  |  |  |  |  |  |  |  |  |  | 10.00% |  |  | 10.00% |  | 10.00% |  |  |  |  |  |  |  |
Two Thousand Twenty Three [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares exercised |  |  |  |  |  |  |  |  |  |  | 272,840 |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of common shares |  |  |  |  |  |  |  |  | 192,500 |  | 192,500 |  |  |  |  |  |  |  |  |  |  |  |  |
Agent [Member] | Agents warrants [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Estimated fair value for adjustment (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 73,018 |  |  |  |  |  |  |  |  |  |
Preferred Class B [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Preferred stock voting per share (in Dollars per share) | $ / shares |  |  |  |  |  |  |  |  | $ 0.25 |  | $ 0.25 |  |  | $ 0.25 |  |  |  |  |  |  |  |  |  |
Escrow Shares |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,857,432 |  |  |  | 5,099,866 |  |  |  |  |  |
Preferred Class B [Member] | Common Stock [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Escrow Shares |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 19,754,347 |  |  |  |  |  |
Common Stock [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share issuance costs |  |  |  |  |  |  |  |  |  |  | 400,000 |  |  |  |  |  |  | 66,519 |  |  |  |  |  |
Number of warrant issued |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,129,566 |  |  |  |  |  |  |  |  |  |
Purchase of each warrant |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 |  |  |  |  |  |  |  |  |  |
Warrant exercise price per share | (per share) |  |  |  |  | $ 0.31 |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0.22 | 0.22 | $ 0.22 |  |  |
Issuance of value (in Dollars) | $ | $ 3,202,823 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares exercised |  | 165,000 |  |  |  |  |  |  |  |  | 80,340 |  |  | 251,101 |  | 251,101 |  |  |  |  |  |  |  |
Additional paid-in capital to share capital (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  | $ 36,751 |  |  | $ 32,097 |  |  |  |  |  |  |  |  |  |
Escrow Shares |  |  |  |  |  |  |  |  |  |  |  |  |  | 11,502,874 |  |  |  |  |  |  |  |  |  |
Common Stock [Member] | Warrant [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from issuance of private placements | $ |  |  |  |  |  |  |  |  |  |  | $ 160,000 |  |  | $ 37,285 |  |  |  |  |  |  |  |  |  |
Number of warrant issued |  |  |  |  |  |  | 1 |  |  |  |  |  |  | 1 |  |  |  |  |  |  |  |  |  |
Purchase of each warrant |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 |  |  |  |  |  |  |  |  |  |
Warrant exercise price per share | (per share) |  |  |  |  |  |  | $ 0.31 |  | $ 0.4 |  | $ 0.4 |  |  |  |  |  |  | $ 0.714 |  | $ 0.39 |  |  |  |
Shares exercised |  |  |  |  |  |  |  |  |  |  | 400,000 |  |  |  |  |  |  | 66,519 |  |  |  |  |  |
Warrant term |  |  |  |  |  |  | 3 years |  |  |  |  |  |  | 5 years |  |  |  |  |  |  |  |  |  |
Common Stock [Member] | ACI Canada Legacy Performance Options [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share issuance costs |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,700,000 |  | 2,700,000 |  |  |  |  |  |  |  |
Shares exercised |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,700,000 |  | 2,700,000 |  |  |  |  |  |  |  |
Option price per share (in Dollars per share) | $ / shares |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 0.01 |  |  |  |  |  |  |  |  |  |
Common Stock [Member] | Spartan Consulting Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share issuance costs |  |  |  |  |  |  |  |  |  |  | 14,558,285 |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of value (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  | $ 3,202,823 |  |  |  |  |  |  |  |  |  |  |  |  |
Common Stock [Member] | General and Administrative Expense [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share issuance costs |  |  |  |  |  |  |  |  |  |  | 928,874 |  |  |  |  |  |  |  |  |  |  |  |  |
Issuance of value (in Dollars) | $ |  |  |  |  |  |  |  |  |  |  | $ 2,273,949 |  |  |  |  |  |  |  |  |  |  |  |  |
Common Stock [Member] | "PP Tranche 5” [Member] | Warrant [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant exercise price per share | $ / shares | $ 0.31 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common Stock [Member] | Over-Allotment Option [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares exercised |  |  |  |  |  |  |  |  |  |  | 80,340 |  |  |  |  |  |  |  |  |  |  |  |  |
Common Stock [Member] | PP Tranche 2 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share issuance costs |  |  |  | 1,596,830 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price | $ / shares |  |  |  | $ 0.22 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from issuance of private placements | $ |  |  |  | $ 351,303 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of warrant issued |  |  |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase of each warrant |  |  |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant exercise price per share | $ / shares |  |  |  | $ 0.31 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common Stock [Member] | PP Tranche 1 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share issuance costs |  |  |  |  | 6,114,058 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price | $ / shares |  |  |  |  | $ 0.22 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from issuance of private placements | $ |  |  |  |  | $ 1,345,093 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of warrant issued |  |  |  |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant exercise price per share | $ / shares |  |  |  |  | $ 0.31 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common Stock [Member] | PP Tranche 3 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share issuance costs |  |  | 229,544 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant exercise price per share | $ / shares |  |  | $ 0.31 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common Stock [Member] | PP Tranche 4 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share issuance costs |  | 9,141,534 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant exercise price per share | $ / shares |  | $ 0.31 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common Stock [Member] | Equity Option [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share issuance costs |  |  |  |  |  |  |  |  |  |  | 192,500 |  |  |  |  |  |  |  |  |  |  |  |  |
Warrant exercise price per share | $ / shares |  |  |  |  |  |  |  |  | $ 0.28 |  | $ 0.28 |  |  |  |  |  |  |  |  |  |  |  |  |
Shares exercised |  |  |  |  |  |  |  |  |  |  | 192,500 |  |  |  |  |  |  |  |  |  |  |  |  |
Common Stock [Member] | Two Thousand Twenty Three [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Shares exercised |  |  |  |  |  |  |  |  |  |  | 251,101 |  |  | 251,101 |  | 251,101 |  |  |  |  |  |  |  |
Common Shares [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share issuance costs |  | 165,000 |  |  |  |  |  |  |  |  |  |  |  | 165,000 |  | 165,000 |  |  |  |  |  |  |  |
Common Shares [Member] | PP Tranche 3 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share issuance costs |  |  | 4,590,903 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Exercise price | $ / shares |  |  | $ 0.22 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from issuance of private placements | $ |  |  | $ 1,009,999 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of warrant issued |  |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase of each warrant |  |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common Shares [Member] | PP Tranche 4 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Stockholders’ Equity (Deficiency) [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Common shares, shares issued |  | 1 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 |  |  |
[1] | In accordance with the Company’s 2023 Option Plan, option holders exercised 272,840 Common Share options on a cashless basis (net exercise) for the issuance of 192,500 Common Shares.
[2] | In accordance with the Company’s 2023 Option Plan, option holders exercised 251,101 Common Share options on a cashless basis (net exercise) for the issuance of 165,000 Common Shares.

X
- Definition Aggregate proceeds percentage. + References No definition available. + Details
Name: | acog_AggregateProceedsPercentage
Namespace Prefix: | acog_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of consulting fee. + References No definition available. + Details
Name: | acog_ConsultingFee
Namespace Prefix: | acog_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Estimated fair value for adjustment + References No definition available. + Details
Name: | acog_EstimatedFairValueForAdjustment
Namespace Prefix: | acog_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of gross proceeds. + References No definition available. + Details
Name: | acog_GrossProceedsPercentage
Namespace Prefix: | acog_
Data Type: | dtr:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represent the number of shares in escrow. + References No definition available. + Details
Name: | acog_NumberOfSharesHeldInEscrow
Namespace Prefix: | acog_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represent the value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + References No definition available. + Details
Name: | acog_PreferredStockVotingSharesParValue
Namespace Prefix: | acog_
Data Type: | dtr:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of reallocated common shares. + References No definition available. + Details
Name: | acog_ReallocatedCommonShares
Namespace Prefix: | acog_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of reclassification of charged to equity. + References No definition available. + Details
Name: | acog_ReclassificationOfChargedToEquity
Namespace Prefix: | acog_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represent amount of reclassification derivative liability per change in functional currency. + References No definition available. + Details
Name: | acog_ReclassificationOfDerivativeLiabilityPerChangeInFunctionalCurrency
Namespace Prefix: | acog_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the warrant repriced amount. + References No definition available. + Details
Name: | acog_RepricedOfWarrants
Namespace Prefix: | acog_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details
Name: | us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details
Name: | us-gaap_ClassOfStockLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Date the warrants or rights are exercisable, in YYYY-MM-DD format. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Exercise price per share or per unit of warrants or rights outstanding. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. + References No definition available. + Details
Name: | us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of warrants or rights outstanding. + References No definition available. + Details
Name: | us-gaap_ClassOfWarrantOrRightOutstanding
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Aggregate number of common shares reserved for future issuance. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_CommonStockCapitalSharesReservedForFutureIssuance
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Aggregate dividends paid during the period for each share of common stock outstanding. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details
Name: | us-gaap_CommonStockDividendsPerShareCashPaid
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | duration

X
- Definition Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_CommonStockSharesIssued
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Description of conversion terms for preferred stock. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7 + Details
Name: | us-gaap_ConvertiblePreferredStockTermsOfConversion
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6 Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(9)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column H)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(9)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(9)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SX 210.12-13(Column G)(Footnote 8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column H)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5C Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SX 210.12-13(Column G)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5 Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5A -Subparagraph (SX 210.12-13A(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column E)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5B Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3 Reference 28: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22 Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10 Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 + Details
Name: | us-gaap_DerivativeLiabilities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of decrease in the fair value of derivatives recognized in the income statement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details
Name: | us-gaap_DerivativeLossOnDerivative
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of cost not yet recognized for nonvested award under share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of expense (income) related to adjustment to fair value of warrant liability. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13 + Details
Name: | us-gaap_FairValueAdjustmentOfWarrants
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(13)(h)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(a)(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)(a)(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details
Name: | us-gaap_GainLossOnSaleOfDerivatives
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of increase (decrease) in equity from change in number of shares or units by investment company. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details
Name: | us-gaap_InvestmentCompanyIncreaseDecreaseFromShareTransaction
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(6)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_LegalFees
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of cash paid for commissions during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_PaymentsForCommissions
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details
Name: | us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details
Name: | us-gaap_ProceedsFromIssuanceOfPrivatePlacement
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details
Name: | us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of proceeds from liquidation of asset held as collateral or by third party expected to cover maximum potential future payment for product warranty. Includes, but is not limited to, separately price extended warranty, product maintenance contract, and warranty obligation incurred in connection with agreed upon specification. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-4 + Details
Name: | us-gaap_ProductWarrantyLiquidationProceedsPercentage
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. + References No definition available. + Details
Name: | us-gaap_SaleOfStockPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Restrictions on equity-based instruments during the vesting period, such as the inability to transfer unvested awards, are not taken into account in estimating the fair value of the award. However, restrictions that remain in effect after an award is vested, such as the inability to transfer or hedge vested options or a prohibition on the sale of outstanding vested shares (or other type of equity) for a period of time, affect the estimate of an award's fair value. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDiscountForPostvestingRestrictions
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The estimated amount of dividends to be paid to holders of the underlying shares (expected dividends) over the option's term. Dividends are taken into account because payment of dividends to shareholders reduces the fair value of the underlying shares, and option holders generally do not receive dividends. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition An excess of the fair value of the modified award over the fair value of the award immediately before the modification. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of share options (or share units) exercised during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details
Name: | us-gaap_StockIssuedDuringPeriodValueNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of increase (decrease) in shares of stock classified as other. + References No definition available. + Details
Name: | us-gaap_StockholdersEquityOtherShares
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details
Name: | us-gaap_WarrantsAndRightsOutstandingTerm
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ClassOfWarrantOrRightAxis=acog_AgentsWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByLiabilityClassAxis=acog_WarrantLiabilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=acog_ACICanadaLegacyPerformanceOptionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=acog_BlackScholesOptionPricingModelMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=us-gaap_StockOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=acog_PrivatePlacementTranche5Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=acog_PPTranche2Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=acog_PrivatePlacementTranche1Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=acog_PrivatePlacementTranche3Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=acog_PrivatePlacementTranche4Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=acog_FirstTrancheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=acog_SecondTrancheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PlanNameAxis=acog_TwoThousandTwoOptionPlanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PlanNameAxis=acog_TwoThousandTwentyThreeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acog_AgentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_PreferredClassBMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=acog_SpartanConsultingAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=acog_CommonSharesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |